Through these studies, we identified a novel molecular mechanism by which mutant p53 de-represses MELK expression in p53-mutant TNBC breast cancers, and identified FOXM1 and MELK as possible targets for the treatment of p53-mutant breast cancers. Here, TP53 is linked to breast cancer.